851726-81-3

Basic information

• Product Name: benzyl {1-[methoxy(methyl)carbamoyl]cyclopropyl}carbamate
• Synonyms: benzyl {1-[methoxy(methyl)carbamoyl]cyclopropyl}carbamate
• CAS NO: 851726-81-3
• Molecular Weight: 278.308
• Mol File: 851726-81-3.mol

Chemical Properties

• CAS DataBase Reference: benzyl {1-[methoxy(methyl)carbamoyl]cyclopropyl}carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl {1-[methoxy(methyl)carbamoyl]cyclopropyl}carbamate(851726-81-3)
• EPA Substance Registry System: benzyl {1-[methoxy(methyl)carbamoyl]cyclopropyl}carbamate(851726-81-3)

Safety Data

• Hazardous Substances Data: 851726-81-3(Hazardous Substances Data)

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 84677-06-5 (benzyloxycarbonylamino)cyclopropanecarboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1439908-49-2 (R,E)-benzyl 1-((tert-butylsulfinylimino)methyl)cyclopropylcarbamate 
• 1374973-52-0 (R)-benzyl 1-(1-aminopropyl)cyclopropylcarbamate hydrochloride 
• 1439908-64-1 benzyl 1-(1-aminopropyl)cyclopropylcarbamate 
• 1439909-59-7 benzyl 1-(1-(5-carbamoyl-4-(m-tolylamino)pyrimidin-2-ylamino)propyl)cyclopropylcarbamate 
• 1439908-67-4 (R)-benzyl 1-(1-amino-2-methylallyl)cyclopropylcarbamate hydrochloride 
• 1439908-62-9 benzyl 1-propionylcyclopropylcarbamate 
• 1616347-65-9 benzyl (1-{[3,5-bis(trifluoromethyl)phenyl](hydroxy)methyl} cyclopropyl)carbamate 
• 1616347-66-0 7-[3,5-bis(trifluoromethyl)phenyl]-6-oxa-4-azaspiro[2.4]heptan-5-one 
• 1616347-62-6 (7R)-7-[3,5-bis(trifluoromethyl)phenyl]-6-oxa-4-azaspiro[2.4]heptan-5-one 
• 1616347-63-7 (7S)-7-[3,5-bis(trifluoromethyl)phenyl]-6-oxa-4-azaspiro[2.4]heptan-5-one 
• 1616347-64-8 benzyl (1-{[3,5-bis(trifluoromethyl)phenyl]carbonyl}cyclopropyl)carbamate 
• 103500-23-8 1-<(benzyloxycarbonyl)amino>cyclopropanecarboxaldehyde 

Relevant articles and documents

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

SPIROCYCLIC CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing at

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROY2.5¨OCTANE RING STRUCTURE

There is provided a novel compound that inhibits the interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits the interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R1 R2, R3, R4, R5, Ar1, and Ar2 in formula (1) each have the same meanings as defined in the specification.

HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.